Xpreza Azacitidine – 100 mg Injection

At a Glance

Generic Name: Azacitidine

Brand Name: Xpreza 100 mg

Strength & Pack Size: 100 mg azacitidine per vial, 1 single-use vial

Dosage Form & Route: Lyophilised powder for subcutaneous injection or intravenous use after reconstitution

Therapeutic Class: Hypomethylating antineoplastic agent (pyrimidine nucleoside analogue)

Primary Indications: Selected myelodysplastic syndromes (MDS), certain AML and chronic myelomonocytic leukaemia (CMML), according to local label

Typical Use in Therapy: Cyclical treatment in specialist haematology units, often as lower-intensity therapy in higher-risk MDS and older AML patients

Mode of Action: Incorporates into RNA/DNA and inhibits DNA methyltransferase, leading to hypomethylation and cytotoxicity in abnormal haematopoietic cells

Key Benefits: Can improve blood counts, delay progression to AML and extend survival in carefully selected patients

Precautions: Requires close monitoring of blood counts, organ function, injection site reactions and infection risk

Storage: Store the vial as per carton instructions, usually refrigerated or below a defined temperature, protected from light until reconstitution

Product Description

Xpreza 100 mg contains azacitidine, a hypomethylating antineoplastic agent used in the treatment of certain myelodysplastic syndromes, selected cases of acute myeloid leukaemia and chronic myelomonocytic leukaemia. Each vial provides 100 mg of azacitidine as a lyophilised powder that must be reconstituted with an appropriate diluent before administration. Xpreza 100 mg azacitidine injection is given in cycles, usually as subcutaneous injections or intravenous infusions in a specialist haematology setting.

For many higher-risk MDS patients and some older adults with AML or CMML, azacitidine offers an important treatment option when intensive induction chemotherapy or transplantation is not appropriate or is being deferred. By targeting abnormal marrow cells and altering gene expression patterns, Xpreza 100 mg azacitidine injection can stabilise disease, improve blood counts, reduce transfusion dependence and delay progression to more aggressive leukaemia in a subset of patients. Treatment is typically long-term and requires patience, as responses may take several cycles to become apparent.

Generic Meds Mart supplies Xpreza 100 mg azacitidine injection in original, sealed oncology packaging from licensed manufacturers and authorised distributors. Vials are shipped in neutral outer cartons that do not mention MDS, AML or azacitidine on the exterior, helping protect patient privacy. Inner packaging retains full information, including brand name, strength, batch number and expiry date, so hospital pharmacies can verify the product before preparing each dose. Pricing is presented in USD, supporting transparent planning for repeated azacitidine cycles that may span many months.

Key Uses

Within the framework of local regulatory approvals and guidelines, Xpreza 100 mg azacitidine injection is used for selected myelodysplastic syndromes, including higher-risk subtypes, and for certain presentations of AML and CMML in adults. Typical candidates include patients with significant cytopenias or higher-risk disease features who may not be suitable for intensive induction chemotherapy. Azacitidine treatment is usually delivered as a 7-day or modified 5–7-day cycle repeated every 28 days, although exact schedules vary by protocol and patient tolerance.

The haematology team will decide whether Xpreza 100 mg azacitidine injection is appropriate based on bone marrow findings, cytogenetics, molecular markers, performance status, comorbidities and patient preferences. Azacitidine may be used as a stand-alone disease-modifying therapy, as a bridge to transplant in selected cases or as a long-term management strategy aimed at improving quality of life and delaying disease progression. It is not a “quick fix” and requires regular clinic visits, laboratory monitoring and supportive care.

How Azacitidine Works in Chemotherapy

Azacitidine, the active ingredient in Xpreza 100 mg injection, is a pyrimidine nucleoside analogue with both hypomethylating and cytotoxic properties. Inside cells, azacitidine is incorporated into RNA and, after conversion to its deoxy form, into DNA. When incorporated into DNA, azacitidine inhibits DNA methyltransferase, an enzyme involved in maintaining normal DNA methylation patterns.

By inhibiting DNA methyltransferase, azacitidine leads to hypomethylation of DNA in rapidly dividing abnormal haematopoietic cells. This can reactivate silenced tumour suppressor genes and alter gene expression profiles in a way that reduces the growth advantage of dysplastic or leukaemic cells. At higher doses, azacitidine also has direct cytotoxic effects, causing damage to abnormal cells that are synthesising DNA.

Through these mechanisms, Xpreza 100 mg azacitidine injection can reduce the burden of abnormal clones in the bone marrow and allow healthier progenitor cells to recover. This may translate into improved blood counts, reduced transfusion needs and delayed transformation to overt leukaemia in some patients. However, the same actions also affect normal dividing cells, which is why careful dose selection and monitoring are essential.

Dosage & Administration

Xpreza 100 mg azacitidine injection must only be prescribed and supervised by haematologists experienced in treating MDS, AML and related disorders. The dose is usually calculated based on body surface area (mg/m²) and adjusted according to response, blood counts and tolerability. After reconstitution, azacitidine can be administered subcutaneously into the abdomen, thigh or upper arm, or given intravenously as an infusion, following the product information and local protocols.

Treatment is typically cyclical, with azacitidine given for several consecutive days followed by a rest period. Patients often receive premedication or supportive antiemetics to reduce nausea and vomiting. Blood counts and biochemistry are checked regularly to guide dose delays or reductions and to decide whether growth factors, transfusions or infection prophylaxis are needed. Xpreza 100 mg azacitidine injection should never be self-prepared or self-administered; all handling and administration are undertaken by trained staff in a clinic or hospital.

Precautions

Before starting Xpreza 100 mg azacitidine injection, the haematology team conducts a thorough review of bone marrow status, blood counts, liver and kidney function, infection history and concomitant medicines. Because azacitidine can cause myelosuppression, patients require ongoing monitoring for neutropenia, thrombocytopenia and anaemia, with timely intervention if counts fall.

Injection site reactions are common with subcutaneous dosing, so patients are advised about rotating injection sites and reporting severe redness, pain or nodules. Nausea, vomiting and diarrhoea are frequent early in treatment, making antiemetics and hydration protocols important. Azacitidine is contraindicated in pregnancy and breastfeeding, and effective contraception is usually recommended during treatment and for a period afterwards. Decisions about continuing, interrupting or stopping Xpreza 100 mg azacitidine injection depend on response, tolerance and evolving clinical status.

Azacitidine Side Effects

Common side effects

Common azacitidine side effects with Xpreza 100 mg injection include low blood counts (neutropenia, thrombocytopenia and anaemia), injection site redness or bruising, nausea, vomiting, diarrhoea or constipation, loss of appetite, fatigue, mild fever, and general weakness. Some patients experience transient kidney or liver test abnormalities, mild headache or injection site pain. These effects are often most noticeable during early cycles and may stabilise or become more manageable as the team refines dosing and supportive care.

Many of these common azacitidine side effects can be addressed with antiemetics, careful hydration, local skin care, growth factor support, transfusions and temporary dose adjustments or delays. Patients are encouraged to keep a symptom diary and bring concerns to clinic visits so that the haematology team can optimise supportive measures.

Serious side effects

Serious azacitidine adverse effects require prompt medical attention. These can include severe or prolonged neutropenia with high risk of infection, sepsis, severe thrombocytopenia with active bleeding, severe gastrointestinal toxicity with dehydration, acute kidney or liver dysfunction, hypersensitivity reactions and, rarely, serious local reactions or tissue damage at injection sites.

Patients should be instructed to contact their treatment centre or emergency services immediately if they develop high fever, chills, shortness of breath, chest pain, uncontrolled vomiting or diarrhoea, black or bloody stools, unusual bleeding or bruising, marked decrease in urine output, confusion or any other alarming symptom. The medical team may need to hold further doses of Xpreza 100 mg azacitidine injection, adjust the regimen or intensify supportive care depending on the severity and suspected cause.

Storage

Xpreza 100 mg azacitidine injection vials should be stored as indicated on the product carton and in the package leaflet, which may include refrigerated storage or a controlled room temperature range. Vials must be kept in the original outer carton to protect from light and should remain out of the reach of children. Reconstituted suspensions or solutions have limited stability and must be prepared and used within the timeframes specified by the manufacturer and local cytotoxic preparation guidelines. Any unused product and materials that have been in contact with azacitidine must be discarded as cytotoxic waste.

Why Buy from Generic Meds Mart

Generic Meds Mart focuses on structured access to essential haematology and oncology medicines such as Xpreza 100 mg azacitidine injection. We source only from licensed manufacturers and authorised distributors that comply with Good Manufacturing Practice and provide full batch traceability. Each vial of Xpreza 100 mg is supplied in sealed original packaging, allowing hospital pharmacies and clinic staff to verify brand, strength, batch number and expiry before preparation.

By listing Xpreza 100 mg azacitidine injection in USD, Generic Meds Mart helps patients and centres plan the cost of repeated treatment cycles. Neutral shipping cartons preserve confidentiality during international delivery, while tracking (where available) allows coordination of shipments with clinic appointments and laboratory monitoring. Our role is to support access and logistics; all decisions about whether, when and how to use azacitidine remain entirely with the treating haematology team.

Order Now

Xpreza 100 mg azacitidine injection is a specialised medicine for MDS, AML and CMML that must never be used without a clear plan from an experienced haematologist. Before arranging supply through Generic Meds Mart, the team should confirm diagnosis, risk category, treatment goals, suitability for azacitidine, proposed dosing schedule and expected duration of therapy. They should also ensure that appropriate monitoring, transfusion support and emergency care pathways are in place.

Once this framework is agreed, the centre or designated purchaser can estimate how many vials of Xpreza 100 mg are needed for the first several cycles. They can then select the corresponding quantity on Generic Meds Mart, add it to the cart and complete secure checkout in USD. Medicines are dispatched in discreet outer packaging with full original labelling inside. Patients and caregivers should never attempt to reconstitute or inject azacitidine themselves unless explicitly trained and authorised by their team, and any new or severe symptoms should be reported promptly for evaluation.

FAQ about Xpreza (Azacitidine)

Q1: What is Xpreza 100 mg used for?
Xpreza 100 mg contains azacitidine, a hypomethylating antineoplastic agent used under haematology supervision in selected myelodysplastic syndromes, certain cases of acute myeloid leukaemia and chronic myelomonocytic leukaemia, according to local product information and guidelines.

Q2: Is Xpreza 100 mg given as an injection or a tablet?
Xpreza 100 mg is supplied as a vial of lyophilised powder that is reconstituted and given as a subcutaneous injection or intravenous dose, depending on protocol. It is not an oral tablet and should only be administered by trained healthcare professionals following the official instructions.

Q3: How long will I need to stay on azacitidine?
Many patients receive Xpreza 100 mg azacitidine injection for multiple cycles, often at least six or more, before treatment is fully evaluated. If there is clinical benefit and side effects remain manageable, therapy may continue for an extended period. The haematology team will review response, blood counts and quality of life regularly to decide how long to maintain azacitidine.

Q4: Can Xpreza 100 mg cure my MDS or AML?
Azacitidine is generally considered a disease-modifying treatment rather than a direct cure for most patients. It can improve blood counts, reduce transfusion needs, delay progression and extend survival in selected cases. In some patients it may be used as a bridge to transplantation, which offers the potential for long-term remission. Your team will explain realistic goals for your individual situation.

Q5: What monitoring is needed during treatment with Xpreza 100 mg?
Patients on Xpreza 100 mg azacitidine injection need regular full blood counts, kidney and liver function tests, clinical assessments for infection and bleeding, and review of injection sites and gastrointestinal symptoms. These checks help the team adjust doses, time cycles appropriately and provide supportive care to manage side effects safely.

Lenalid Lenalidomide – 5 mg, 10 mg, 15 mg, 25 mg Capsules (1 pack / 30 caps)

At a Glance

Generic Name: Lenalidomide

Brand Name: Lenalid

Strength & Pack Options: Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg, Lenalid 25 mg – each 1 pack / 30 capsules

Dosage Form: Oral tablets for systemic use

Therapeutic Class: Immunomodulatory and anticancer agent (IMiD)

Main Indications: Multiple myeloma, selected myelodysplastic syndromes and mantle cell lymphoma as indicated

Use in Therapy: Combination or maintenance chemotherapy regimens under haematology or oncology supervision

Prescription Status: Prescription-only cytotoxic and teratogenic medicine

Supplied By: Licensed manufacturers and authorised distributors

Storage: Store below 25 °C in a dry place away from light and moisture

Product Description

Lenalid is a range of generic lenalidomide tablets available in four strengths:
Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg and Lenalid 25 mg, each supplied as
1 pack / 30 tablets. Lenalidomide is an immunomodulatory and anticancer medicine used mainly in the treatment of
multiple myeloma and other haematological conditions. It is given as part of protocol-based chemotherapy or maintenance regimens
designed by specialist haematologists and oncologists.

In multiple myeloma, lenalidomide is widely used in combination with other agents such as dexamethasone and proteasome inhibitors,
and as maintenance therapy after frontline treatment or transplant. The availability of
Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg and Lenalid 25 mg tablets allows your team to match the
strength and total daily dose to the specific cycle, kidney function and tolerance over time. Lower strengths such as
Lenalid 5 mg and Lenalid 10 mg are often used in maintenance regimens or myelodysplastic syndromes, while higher strengths like
Lenalid 25 mg and Lenalid 15 mg may be used during induction or consolidation according to recognised protocols.

As a generic lenalidomide 5 mg / 10 mg / 15 mg / 25 mg product, Lenalid contains the same active ingredient as originator lenalidomide but may offer
a more accessible option in USD for long-term therapy. Each pack of Lenalid lenalidomide tablets is supplied in sealed blisters with clear labelling of strength,
batch number and expiry date. Generic Meds Mart sources Lenalid only from licensed manufacturers and authorised distributors that comply with recognised GMP standards.

When you buy Lenalid online from Generic Meds Mart, you remain under the care of your own haematology or oncology team.
We do not design or modify chemotherapy regimens; our role is to provide structured access to Lenalid 5 mg, Lenalid 10 mg,
Lenalid 15 mg and Lenalid 25 mg tablets exactly as specified in your written treatment plan.

Key Uses

Lenalid lenalidomide tablets in 5 mg, 10 mg, 15 mg and 25 mg strengths are typically used for the following indications under specialist supervision:

• Multiple myeloma in combination regimens and as long-term maintenance therapy
• Selected myelodysplastic syndromes, particularly with specific cytogenetic profiles
• Mantle cell lymphoma and other haematological malignancies where lenalidomide is recommended
• Maintenance therapy following autologous stem cell transplant or frontline treatment, often using Lenalid 10 mg or Lenalid 5 mg

Your specialist will determine which strength – Lenalid 25 mg, Lenalid 15 mg, Lenalid 10 mg or Lenalid 5 mg – is appropriate at each stage of your regimen.

How Lenalidomide Works in Chemotherapy

Lenalidomide is a second-generation immunomodulatory drug (IMiD) with multiple mechanisms of action.
Although often discussed alongside oral chemotherapy, Lenalid lenalidomide acts differently from traditional cytotoxic agents.
It modifies the immune response, influences the bone marrow microenvironment and directly affects malignant plasma cells.

Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg and Lenalid 25 mg tablets can enhance T-cell and natural killer cell activity,
leading to stronger immune-mediated attack on tumour cells. Lenalidomide also interferes with the growth of blood vessels within the marrow and alters cytokine signalling.
At the cellular level, lenalidomide binds to specific proteins that control degradation of key transcription factors, promoting apoptosis of malignant plasma cells.

These combined effects make lenalidomide a central component of modern multiple myeloma chemotherapy and maintenance regimens,
but they also explain some of its side effects, such as bone marrow suppression and increased clotting risk.

Dosage & Administration

Dosing of Lenalid is highly individual and must always follow the protocol set by your haematology or oncology team.
The choice among Lenalid 25 mg, Lenalid 15 mg, Lenalid 10 mg and Lenalid 5 mg depends on indication, kidney function,
combination partners and tolerance.

• Lenalid lenalidomide tablets are usually given in 28-day cycles, with treatment days and rest days clearly defined in your calendar.
• Take Lenalid tablets by mouth once daily on the prescribed days, with water, at approximately the same time each day.
• Swallow Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg and Lenalid 25 mg tablets whole; do not crush, split or chew them unless instructed.
• Follow the cycle plan, including blood test dates and clinic visits, exactly as given.
• If you miss a dose, follow instructions from your treatment centre; do not double the next dose without explicit advice.

Your doctor may reduce the dose from Lenalid 25 mg to Lenalid 15 mg, Lenalid 10 mg or Lenalid 5 mg if blood counts fall,
kidney function changes or side effects emerge.

Precautions

Lenalidomide is strongly teratogenic and requires strict safety measures. Before taking Lenalid, inform your care team about your full medical history and all medicines you use. Key precautions include:

• Pregnancy prevention: Women who are pregnant or may become pregnant must not take Lenalid lenalidomide tablets. Contraception and regular pregnancy testing are often mandatory.
• Blood clots: Lenalid increases the risk of deep vein thrombosis and pulmonary embolism, particularly when combined with steroids.
• Low blood counts: Neutropenia, anaemia and thrombocytopenia are common, especially at higher doses such as Lenalid 25 mg or Lenalid 15 mg.
• Infection risk: Fever or signs of infection during Lenalid therapy require urgent medical assessment.
• Kidney function: Dose adjustments between Lenalid 5 mg, 10 mg, 15 mg and 25 mg are often needed in renal impairment.
• Drug interactions: Your team must know about all prescription medicines, over-the-counter products and supplements you are taking.

Lenalidomide Side Effects

Common side effects

Common side effects of Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg and Lenalid 25 mg can include:

• Neutropenia and increased infection risk
• Thrombocytopenia with bruising or bleeding
• Anaemia, tiredness and shortness of breath
• Mild nausea, constipation or diarrhea
• Rash or mild skin reactions
• Muscle cramps, weakness and fatigue
• Mild peripheral neuropathy (tingling or numbness in hands and feet)

Many of these effects are managed through blood test monitoring, dose reductions and supportive care.

Serious side effects

Serious side effects of lenalidomide require urgent medical attention and may include:

• Signs of blood clots: chest pain, sudden shortness of breath, coughing blood, painful swollen leg
• High fever, chills or severe infection symptoms
• Severe skin reactions, blistering or extensive rash
• Marked bleeding or bruising, nosebleeds or blood in urine or stools
• Sudden confusion, visual changes or neurological symptoms

If you experience any of these reactions while taking Lenalid lenalidomide tablets, seek emergency care immediately and contact your treatment centre.

Storage

• Store Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg and Lenalid 25 mg tablets at room temperature below 25 °C.
• Keep tablets in original blisters and cartons, protected from moisture and light.
• Keep all lenalidomide tablets away from children, pregnant women and anyone not involved in your care.
• Do not use after the expiry date printed on the packaging.

Ask your pharmacist or oncology centre how to safely dispose of unused or expired Lenalid.

Why Buy from Generic Meds Mart

Generic Meds Mart provides reliable access to Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg and Lenalid 25 mg lenalidomide tablets
at transparent prices in USD. We source only from licensed manufacturers and authorised distributors that comply with recognised GMP standards.

When you buy Lenalid online from Generic Meds Mart, you benefit from:

• All key lenalidomide strengths on one variable product page (5 mg, 10 mg, 15 mg, 25 mg)
• Plain, discreet outer packaging for international delivery
• Tracked shipping options to many destinations
• Clear, structured product information to support discussions with your haematology or oncology team
• Customer support for ordering, payment and delivery questions

Order Now

Lenalid lenalidomide tablets are prescription-only cytotoxic and teratogenic medicines and must be used strictly under specialist supervision.
Before you order Lenalid 5 mg, 10 mg, 15 mg or 25 mg online, ensure that your haematologist or oncologist has confirmed the indication, dose and cycle length.

Select the required strength – Lenalid 5 mg (1 pack / 30 tablets), Lenalid 10 mg (1 pack / 30 tablets),
Lenalid 15 mg (1 pack / 30 tablets) or Lenalid 25 mg (1 pack / 30 tablets) – add it to your cart and complete the secure checkout on
Generic Meds Mart. Your order will be processed, packed discreetly and shipped with tracking where available. All treatment decisions, dose changes and monitoring remain the responsibility of your healthcare team.

Azadine 100 mg Azacitidine Injection (1 vial)

At a Glance

Generic Name: Azacitidine

Brand Name: Azadine 100 mg

Strength & Pack Size: 100 mg azacitidine, 1 vial of lyophilised powder for injection

Dosage Form & Route: Powder for suspension or solution, for subcutaneous (SC) or intravenous (IV) administration after reconstitution

Therapeutic Class: Hypomethylating antineoplastic agent

Primary Indications: Myelodysplastic syndromes (MDS) and selected acute myeloid leukemia (AML) cases, as per local label

Typical Patient Setting: Adults treated in specialist haematology–oncology centres with access to intensive monitoring

Mode of Action: Inhibits DNA methyltransferase, leading to hypomethylation and direct cytotoxic effects on abnormal marrow cells

Key Benefits: Proven improvement in blood counts and survival in higher-risk MDS and certain AML populations when used appropriately

Precautions: Requires close monitoring of blood counts, organ function and injection site reactions; hospital infrastructure recommended

Storage: Store in the original carton at the temperature stated in the leaflet; protect from light and follow reconstitution stability guidance

Product Description

Azadine 100 mg azacitidine injection is a hypomethylating agent used in the treatment of myelodysplastic syndromes (MDS) and in selected acute myeloid leukemia (AML) settings according to local prescribing information and specialist guidelines. Azacitidine targets abnormal bone marrow cells by interfering with DNA methylation and exerting direct cytotoxic effects, helping to restore more normal blood cell production over time.

Each vial of Azadine 100 mg contains 100 mg of azacitidine as a sterile lyophilised powder that must be reconstituted with an appropriate diluent before administration. Depending on local protocols, the reconstituted suspension or solution is given either subcutaneously or intravenously in repeated treatment cycles. Because of the risks of myelosuppression, infection and other serious side effects, Azadine 100 mg injection is used under the supervision of experienced haematologists and oncologists in facilities that can provide supportive care and regular monitoring.

When you buy Azadine 100 mg online from Generic Meds Mart, you receive original manufacturer vials in sealed cartons with clearly visible batch numbers and expiry dates. Products are sourced only from licensed distributors experienced in oncology and haematology supply chains. Outer shipping boxes are neutral, without visible references to MDS, AML or chemotherapy, to protect patient privacy, while maintaining complete traceability for pharmacies and clinics. Our mission is to support access and logistics; all treatment decisions remain with your specialist team.

Key Uses

Azadine 100 mg azacitidine injection is used in adults for myelodysplastic syndromes (MDS) and certain acute myeloid leukemia (AML) presentations, as defined in regional labels and guidelines. Typical indications include:

• Myelodysplastic syndromes (MDS), including subtypes with excess blasts, where disease-modifying hypomethylating therapy is indicated.
• Selected cases of AML, particularly those evolving from MDS or with lower blast percentages, where azacitidine-based regimens are supported by local protocols.

The choice to use Azadine 100 mg is individualized and considers patient age, performance status, cytogenetic and molecular risk, comorbidities and eligibility for alternative options such as intensive chemotherapy or stem cell transplantation. Azacitidine injection is often chosen for higher-risk MDS or for patients in whom traditional intensive regimens would be inappropriate or poorly tolerated.

How Azacitidine Works in Chemotherapy

Azacitidine, the active ingredient in Azadine 100 mg, is a cytidine analogue that exerts its antineoplastic effects through dual mechanisms. At lower concentrations, azacitidine incorporates into RNA and DNA and inhibits DNA methyltransferase, leading to hypomethylation of DNA. This hypomethylation can reactivate silenced tumour suppressor genes and modify abnormal gene expression patterns in dysplastic bone marrow cells.

At higher concentrations, azacitidine has direct cytotoxic effects on rapidly dividing cells, leading to cell death. In the context of myelodysplastic syndromes and certain AML subtypes, these mechanisms help reduce the burden of abnormal progenitor cells and support recovery of more normal haematopoiesis over repeated treatment cycles. Response to azacitidine therapy builds gradually, so clinicians often continue treatment for multiple cycles before judging benefit, provided tolerance and safety profiles remain acceptable.

Dosage & Administration

The dosing of Azadine 100 mg azacitidine injection is defined by body surface area and local prescribing information. A commonly used regimen in MDS involves administration of azacitidine for a set number of days in a 28-day cycle, given either subcutaneously or intravenously. Regimens, exact dose in mg/m², route and number of treatment cycles may vary based on label, institutional practice and individual patient factors.

Azadine vials must be reconstituted with the recommended diluent, using aseptic technique, and the resulting suspension or solution is administered within defined stability periods. Administration is performed only by trained healthcare professionals. Blood counts, kidney and liver function, as well as clinical status, are closely monitored before and during each cycle. Dose delays, reductions or interruptions may be necessary in response to myelosuppression, infections or other toxicities. Patients should never attempt to reconstitute or administer azacitidine themselves.

Precautions

Before starting Azadine 100 mg, your haematology team will review your full medical history, including prior treatments, performance status, infection risk, kidney and liver function and concurrent medications. Baseline blood counts and biochemistry help guide eligibility and dosing. Because azacitidine can cause profound myelosuppression, the risk of infections and bleeding must be considered, and prophylactic or early-intervention strategies may be used where appropriate.

Patients may be counselled about the potential need for blood or platelet transfusions, antimicrobial prophylaxis, hospital admission during infections and frequent laboratory monitoring. Azacitidine injection is not suitable for all patients; those with severe organ dysfunction or uncontrolled infections may require stabilisation before treatment or alternative approaches. Women and men of childbearing potential are usually advised to use effective contraception during treatment and for a period afterwards, as azacitidine can harm a developing baby. Breastfeeding is generally not recommended during therapy.

Azacitidine Side Effects

Common side effects

Common azacitidine side effects during Azadine 100 mg therapy include nausea, vomiting, diarrhoea or constipation, loss of appetite, fatigue, weakness, injection site reactions (for subcutaneous administration), mild rash, headache and low-grade fever. Haematologic side effects are very frequent and may involve reduced white cells, red cells and platelets, leading to higher risk of infections, anaemia and bruising or bleeding.

Many of these reactions can be managed with supportive medicines such as antiemetics, analgesics, topical measures for injection sites, growth factors in selected cases, transfusions and dose adjustments or cycle delays. Patients are encouraged to report any new or worsening symptoms promptly so that the medical team can intervene early and adjust treatment if needed.

Serious side effects

Serious azacitidine adverse effects require urgent medical attention and may include severe neutropenia with life-threatening infections, sepsis, severe thrombocytopenia with major bleeding, serious allergic reactions, pronounced liver or kidney injury, severe gastrointestinal events and rare but significant cardiac complications.

Warning signs to watch for include high or persistent fever, chills, severe sore throat, shortness of breath, chest pain, confusion, uncontrolled bleeding or bruising, black stools, vomiting blood, severe abdominal pain, markedly reduced urine output, yellowing of the skin or eyes or sudden swelling. If any of these occur during treatment with Azadine 100 mg azacitidine injection, emergency medical help should be sought immediately and healthcare professionals informed that you are receiving a hypomethylating agent.

Storage

Azadine 100 mg vials should be stored in their original cartons at the temperature specified in the product leaflet, protected from light and kept out of reach of children. They should not be frozen. After reconstitution, the azacitidine suspension or solution has a limited stability window and specific storage conditions, which must be followed closely by the pharmacy and infusion or day-care unit. Unused reconstituted product and materials used for preparation and administration must be disposed of as cytotoxic waste according to local regulations.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on improving access to essential haematology–oncology therapies such as Azadine 100 mg azacitidine injection, particularly in regions where availability and pricing can be barriers. We collaborate only with licensed manufacturers and authorised distributors who follow recognised quality and safety standards and provide full batch traceability. By supplying Azadine 100 mg in sealed original packaging, we support hospital pharmacies and clinics in verifying product authenticity and integrity.

Orders are processed in USD using secure online payment systems. Shipments are prepared in neutral outer packaging without visible oncology references, with the option for tracked delivery where available. This helps centres plan treatment cycles and ensure that azacitidine vials arrive in time for scheduled therapy. Our role is purely logistical; decisions about whether azacitidine is suitable, how many cycles to give and how to manage side effects are entirely the responsibility of the treating haematology–oncology team.

Order Now

Before arranging to buy Azadine 100 mg azacitidine injection online from Generic Meds Mart, you should have a confirmed diagnosis of myelodysplastic syndrome or AML where azacitidine is recommended, and a clear treatment plan from your specialist detailing dose, route, schedule and monitoring requirements. Your team will explain how azacitidine therapy fits into your overall care, expected benefits, potential risks and the importance of regular follow-up.

Once this plan is in place, your clinic or you, in agreement with your doctors, can determine how many Azadine 100 mg vials are needed per cycle and for the planned number of cycles. After you select the required quantity, you can complete secure checkout in USD. You should never start, stop or modify azacitidine treatment on your own; any changes must be guided by your haematology–oncology team. Generic Meds Mart exists to provide a discreet, reliable supply channel for Azadine 100 mg azacitidine injection, while all complex clinical decisions remain with your specialists.

FAQ about Azadine (Azacitidine)

Q1: What conditions is Azadine 100 mg used to treat?

Azadine 100 mg contains azacitidine, a hypomethylating agent used for myelodysplastic syndromes (MDS) and selected acute myeloid leukemia (AML) cases in adults, according to local prescribing information and specialist guidelines.

Q2: Is Azadine 100 mg an infusion or an injection under the skin?

Azadine 100 mg azacitidine can be given as a subcutaneous injection or as an intravenous infusion, depending on local protocols and patient factors. The powder in the vial is reconstituted by healthcare professionals, who then administer it using the route and schedule defined in your treatment plan.

Q3: How many treatment cycles of azacitidine will I need?

The number of azacitidine cycles varies between patients. Many people require multiple cycles, often at least six, before a full assessment of response is made, provided side effects remain manageable. Your haematology team will explain how many cycles they recommend and how they will evaluate benefit over time.

Q4: Will I need to stay in hospital for Azadine treatment?

Some patients receive Azadine 100 mg as day-care treatment, while others may need hospital admission, especially early in therapy or if complications arise. Decisions about inpatient versus outpatient management depend on your overall health, blood counts, infection risk and local practice.

Q5: Can Azadine 100 mg cure my disease?

In some patients, azacitidine can lead to durable remissions and significantly improved survival, but not everyone achieves a complete cure with hypomethylating therapy alone. For some individuals, Azadine 100 mg may serve as a bridge to other treatments such as stem cell transplantation. Your haematologist is best placed to discuss realistic goals of therapy in your specific situation.

Q6: Is Azadine 100 mg the same as Vidaza (Generic Vidaza)?
Azadine 100 mg is Generic Vidaza — it contains the same active ingredient (azacitidine) as Vidaza. It’s used for the same purpose at the same strength, while differences may be in manufacturer, inactive ingredients (excipients), vial appearance, and packaging. If you’re switching between products, confirm the substitution with a qualified healthcare professional.